



PRODUCT KEY FACTS

BNP Paribas Funds Health Care Innovators
March 2022

- ***This statement provides you with key information about this product.***
- ***This statement is a part of the offering document and should be read in conjunction with the Prospectus, Hong Kong Covering Document and Information for Hong Kong Investors.***
- ***You should not invest in this product based on this statement alone.***

Quick facts

| | | | |
|---|--|---------------------------|---|
| Management Company: | BNP PARIBAS ASSET MANAGEMENT Luxembourg | | |
| Fund Manager: | Internal and/or external delegation to one or more portfolio managers as described in the "General Information" section of the Prospectus and the "Management and Sub-Delegation" section of the Hong Kong Covering Document and Information for Hong Kong Investors | | |
| Custodian: | BNP Paribas Securities Services, Luxembourg Branch | | |
| Ongoing charges over a year#: | Classic | | 1.98% |
| Base currency: | EUR | Dealing frequency: | Daily |
| Financial year end of this sub-fund: | 31 December | Dividend policy: | Capitalisation shares – No dividend distribution (income, if any, will be reinvested) Distribution shares - Dividend, if declared, will be paid Distributions may be paid out of capital which may result in an immediate reduction of the sub-fund's net asset value per share |
| | Min. investment: | None | |

The ongoing charges figure is calculated based on expenses for the year ended at 31 December 2021. This figure may vary from year to year. The ongoing charge is calculated by adding all direct fees, indirect fees and external fees of the sub-fund and then divided by the average net assets. Direct fees refer to charges and payment directly borne by the sub-fund such as operating costs, remuneration and payment to key operators and service providers. Indirect fees refer to the ongoing charges of the underlying funds which the sub-fund invests. External fees refer to any remuneration of the management company or other party that derives from fee-sharing arrangement.

What is this product?

This sub-fund is a fund constituted in the form of a mutual fund. It is incorporated under Luxembourg law and regulated by the Commission de Surveillance du Secteur Financier (CSSF).

Objective and Investment Strategy

Objective

To increase the value of its assets over the medium term by investing in healthcare innovative companies.

Strategy

At all times, this sub-fund invests at least 75% of its assets in equities and/or equity equivalent securities (such as participation rights which refer to equity instruments like bonus right and/or subscription rights (which may result from a corporate action)) issued worldwide by health care companies that enable or benefit from innovative technologies, including, but not limited to, advances in genetic sequencing, drug delivery, miniaturization, bio-compatible materials, haptics and information technology to the healthcare field.

The remaining portion, namely a maximum of 25% of its assets, may be invested in any other securities, money market instruments or cash, provided that investments in debt securities of any kind do not exceed 15% of its assets, and up to 10% of its assets may be invested in collective investment schemes.

To further elaborate, the investment manager will select investments for the sub-fund which have an aim to create shareholder value. Fundamental company research will be conducted to assess a company's earnings prospects and determine an estimate of intrinsic value.

The sub-fund seeks to invest in companies which innovate or benefit from healthcare innovation including but not limited to advances in genetic sequencing, drug delivery, miniaturization, bio-compatible materials, haptics and information technology in the healthcare field.

There are companies that have a strong health care component to them in other sectors that the sub-fund will also consider for investment, such as the technology and consumer sectors. These could include stocks that are not categorised as health care stocks by MSCI, but have a large exposure to the health care industry. For example, a technology company that has a medical device subsidiary or drug store that is categorised as a consumer retailer, but that has a large portion of its revenue that is tied to its pharmacy benefit management business.

The Investment Manager applies BNP PARIBAS ASSET MANAGEMENT's Sustainable Investment Policy, which takes into account Environmental, Social and Governance criteria in the investment process of the sub-fund.

It is unlikely that the sub-fund will invest in debt securities. Even if so, the sub-fund will invest in investment grade debt securities. Moreover, the sub-fund does not contemplate to invest more than 10% of its net asset value in securities issued by or guaranteed by any single country (including its government, a public or local authority of that country) with a credit rating below investment grade and/or unrated.

Use of Derivatives/Investment in Derivatives

The sub-fund's net derivative exposure may be up to 50% of the sub-fund's NAV.

What are the key risks?

Investment involves risks. Please refer to the offering document for details including the risk factors.

Sector Concentration Risk

- The sub-fund's investments are concentrated in healthcare innovative companies. This may result in

BNP Paribas Funds Health Care Innovators

greater volatility than funds which comprise broad-based investments. The sub-fund may be more susceptible to adverse fluctuations in value resulting from adverse condition in the healthcare sector and the sub-fund's value may be adversely affected.

Risk linked to Equity Market

- Investments in equity include significant fluctuations in prices, negative information about the issuer or market. Moreover, these fluctuations are often amplified in the short term and may have a negative impact on the performance of the overall portfolio at a given time. There is no guarantee that investors will see an appreciation in value. The value of investments of the sub-fund may go down and it is possible that investors will not recover their initial investment.

Risk related to Investments in Some Countries

- Investments in some countries (China, India, Indonesia, Japan, Saudi Arabia and Thailand) involve risks linked to the restrictions imposed on foreign investors and counterparties, higher market volatility and the risk of lack of liquidity.

Emerging Market Risk

- The sub-fund may invest in emerging markets (examples of emerging countries include China, India, Indonesia, Korea, Chile, Hungary, Mexico and Poland etc.). Investing in emerging markets is likely to be subject to a higher than average volatility, less liquidity and greater sensitivity than investing in more developed markets due to, among other factors, greater uncertainty, greater political, tax, economic, social, foreign exchange, liquidity and regulatory risks. The price fluctuations of the investments are often amplified in the short term and the value of investments of the sub-fund may go down.

Risk associated with investments in financial derivative instruments

- Risk associated with financial derivative instruments include counterparty/credit risk, liquidity risk, valuation risk, volatility risk and over-the-counter transaction risk. The leverage element/component of a financial derivative instrument can result in a loss significantly greater than the amount invested in the financial derivative instruments by the sub-fund. Exposure to financial derivative instruments may lead to a high risk of significant loss by the sub-fund.

Liquidity Risk

- Investments made by the sub-fund may become illiquid. It may not be possible to sell or buy these investments quickly enough to prevent or minimize a loss in the sub-fund.

Currency Exchange Risk

- The sub-fund may hold assets denominated in currencies that differ from the base currency, and may be affected by exchange rate fluctuations between the base currency and the other currencies and by changes in exchange rate controls. A depreciation of the denomination currency will lead to a depreciation in the exchange value of the security. When the manager is willing to hedge the currency exchange risk of a transaction, there is no guarantee that such operation will be completely effective and the sub-fund's value may be adversely affected.

Operational & Custody Risk

- Some markets are less regulated than most of the international markets; hence, the services related to custody and liquidation for the sub-fund on such markets could be more risky. In the event of a custodian default, the sub-fund may suffer a delay in recovering its assets, pending the resolution of the relevant default or bankruptcy proceedings.

Risk in connection with Dividend Payment


- The Management Company may at its discretion pay dividends out of the capital of the sub-fund. Payments of dividends out of capital amounts to a return or withdrawal of part of an investor's original investment or from any capital gains attributable to that original investment. Any distributions involving payment of dividends out of the sub-fund's capital may result in an immediate reduction of the net asset value per share. The Management Company may amend the dividend policy subject to the SFC's prior approval and by giving not less than one month's notice to investors.

BNP Paribas Funds Health Care Innovators

Investment Risk

- When investing in a fund, there is a risk that the final outcome may deviate from the initial expectations. The sub-fund's investment portfolio may fall in value and therefore may suffer losses. In addition, there is no guarantee of principal repayment.

How has the fund performed?



- Past performance information is not indicative of future performance. Investors may not get back the full amount invested.
- The computation basis of the performance is based on the calendar year end, NAV-to-NAV, with dividend reinvested.
- Classic Capitalisation, being a share class with the same reference currency as the sub-fund with the longest track record among all share classes and not restricted to certain types of clients, is selected as the representative share class.
- These figures show by how much the Classic Capitalisation share class increased or decreased in value during the calendar year being shown. Performance data has been calculated in EUR including ongoing charges and excluding subscription fee and redemption fee you might have to pay.
- Where no past performance is shown there was insufficient data available in that year to provide performance.
- BNP Paribas Funds Health Care Innovators launch date: 21 May 2013
- Classic Capitalisation share class launch date: 21 May 2013
- On 27 May 2013, BNP Paribas Funds Health Care Innovators absorbed a Luxembourg fund which is not authorized by the SFC.

Is there any guarantee?

This sub-fund does not have any guarantees. You may not get back the full amount of money you invest.

What are the fees and charges?

Charges which may be payable by you

You may have to pay the following fees when dealing in the shares of the sub-fund.

| Fee | What you pay |
|---------------------------------------|---|
| Subscription fee (Entry cost) | Up to 3% of the net asset value of the relevant share class subscribed |
| Switching fee (Conversion fee) | Up to 1.5% of the net asset value of the relevant share class converted |
| Redemption fee (Exit cost) | Nil |

Ongoing fees payable by the sub-fund

The following expenses will be paid out of the sub-fund. They affect you because they reduce the return you get on your investments.

| | Annual rate (as a % of the net asset value of the relevant share category) |
|---|--|
| Management fee | "Classic" categories – Up to 1.50% |
| Custodian fee | Included in Other costs |
| Performance fee | Not applicable |
| Administration fee | Included in Other costs |
| Other costs (Other costs cover the general asset custody expenses payable to the custodian and the daily administration expenses) | Up to 0.40% for all share categories |

Other fees

You may have to pay other fees when dealing in the shares of the sub-fund.

BNP Paribas Funds Health Care Innovators

Additional Information

- You generally buy and redeem shares at the sub-fund's next determined subscription price and redemption price through your authorised distributor after the transaction servicing agent receives your request via your authorised distributors in good order on or before 6 pm (Hong Kong time) on a Hong Kong business day. Investors should note that different distributors may have different dealing cut-off which may be earlier than the time specified in this document. Investors should check with the relevant authorised distributors accordingly.
- The net asset value of this sub-fund is calculated and the price of shares published daily on the website at <http://www.bnpparibas-am.hk>.
- Investors may obtain the past performance information of other share classes offered to Hong Kong investors from the website at <http://www.bnpparibas-am.hk>.
- The compositions of the dividends for the last 12 months are available from the Hong Kong representative on request and also on the website at <http://www.bnpparibas-am.hk>.
- Investors may obtain information on the intermediaries from our hotline (852) 2533 0088.

Important

If you are in doubt, you should seek professional advice.

The SFC takes no responsibility for the contents of this statement and makes no representation as to its accuracy or completeness.